Program
adebrelimab
Also written as “SHR-1316”, “Adebrelimab” and “Adebrelimab Injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Pancreatic Neoplasms · Neoplasms · Breast Neoplasms, led by 2 companies.
Drug pageAdebrelimab: every studyAll 205 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 4938 open or running | phase 3since Oct 16, 2018 | Apr 8, 2017 | Dec 2026phase 2 · NCT05482568 |
| Hansoh Pharmaceutical Groupits history only | 22 open or running | phase 2since Aug 13, 2026 | Jul 3, 2025 | Mar 30, 2028phase 2 · NCT07824882 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 36 earlier studies, Apr 8, 2017 to Sep 4, 2025.
- Dec 9, 2019Named adebrelimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, SHR-1316
- Nov 13, 2025Phase 3 study in Advanced Biliary Tract CancerJiangsu HengRui Medicine · NCT07229625 · 604 planned · China
- Nov 14, 2025Phase 2 study in Lung NeoplasmsJiangsu HengRui Medicine · NCT07241767 · 200 planned · China
- Dec 9, 2025Phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithJiangsu HengRui Medicine · NCT07296341 · 60 planned · China
- Jan 30, 2026Phase 3 study in Carcinoma, Transitional CellJiangsu HengRui Medicine · NCT07393542 · 453 planned · China
- Feb 25, 2026Phase 3 study in Locally Advanced Resectable Rectal CancerJiangsu HengRui Medicine · NCT07454720 · 165 planned · China
- Apr 3, 2026Phase 3 study in Locally Advanced Gastric or Gastroesophageal Junction CancerJiangsu HengRui Medicine · NCT07522151 · 874 planned · China
- Jun 25, 2026Phase 3 study in Triple Negative Breast NeoplasmsJiangsu HengRui Medicine · NCT07679360 · 1,000 planned · China
- Jul 2, 2026Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT07691762 · 690 planned · China
- Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerJiangsu HengRui Medicine · NCT07704645 · 180 planned · China
- Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedHansoh Pharmaceutical Group · NCT07824882 · 76 planned · China
- Aug 28, 2026Phase 2 study in Small Cell Lung CarcinomaJiangsu HengRui Medicine · NCT07798947 · 120 planned · China
- Sep 2, 20262 phase 2 studiesJiangsu HengRui Medicine · NCT07806058, NCT07863167
- Oct 19, 20262 phase 3 studiesJiangsu HengRui Medicine · NCT07896005, NCT07900789
- Oct 29, 2026Primary completion moved from 2031-04 to 2031-09Date moved laterphase 3 · +5 months · NCT07691762
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourJiangsu HengRui Medicine · NCT06915142
- Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerJiangsu HengRui Medicine · NCT05482568
- Dec 30, 2026Primary completion: phase 2 study in Biliary Tract NeoplasmsJiangsu HengRui Medicine · NCT06465563
- Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckJiangsu HengRui Medicine · NCT07059221
TargetBeta
“An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 51 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07900789Systemic Treatment-naïve Pancreatic Cancer · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Nov 30, 2030 | 825 |
| NCT07896005Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Feb 2031 | 436 |
| NCT07863167Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2028 | 660 |
| NCT07806058Pancreatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2028 | 140 |
| NCT07798947Small Cell Lung Carcinoma · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2028 | 120 |
| NCT07824882Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Mar 30, 2028 | 76 |
| NCT07704645Resectable Non-small Cell Lung Cancer · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Jun 2028 | 180 |
| NCT07691762Carcinoma, Hepatocellular · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2031 | 690 |
| NCT07679360Triple Negative Breast Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2030 | 1,000 |
| NCT07522151Locally Advanced Gastric or Gastroesophageal Junction Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2029 | 874 |
| NCT07454720Locally Advanced Resectable Rectal Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Nov 2032 | 165 |
| NCT07393542Carcinoma, Transitional Cell · China | 3 | Recruiting | Jiangsu HengRui Medicine | Jan 31, 2028 | 453 |
| NCT07296341Locally Advanced or Metastatic Pancreatic Cancer With · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2027 | 60 |
| NCT07241767Lung Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Nov 2027 | 200 |
| NCT07229625Advanced Biliary Tract Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2029 | 604 |
| NCT07168200Advanced Cervical Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 2028 | 720 |
| NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Jiangsu HengRui Medicine | Oct 2030 | 600 |
| NCT07111832Triple Negative Breast Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Mar 2028 | 400 |
| NCT07073534Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2027 | 203 |
| NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Apr 30, 2026 | 50 |
| NCT07059221Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Jiangsu HengRui Medicine | Mar 2027 | 210 |
| NCT07009457Widespread Small Cell Lung Cancer · China | 1 | Active, not recruiting | Jiangsu HengRui Medicine | Sep 2027 | 24 |
| NCT06915142Advanced Malignant Tumour · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 300 |
| NCT06879145Muscular Invasive Bladder Cancer (MIBC) · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2031 | 740 |
| NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Feb 28, 2026 | 60 |
| NCT06465563Biliary Tract Neoplasms · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 30, 2026 | 93 |
| NCT06474468Esophageal Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2026 | 148 |
| NCT06417554Advanced Solid Tumors · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2031 | 80 |
| NCT06350006CLDN18.2-positive Advanced Solid Tumor · China | 1 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2027 | 924 |
| NCT06335355Non-squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Oct 2028 | 401 |
| NCT06247956Esophageal Squamous Cell Carcinoma · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 30, 2025 | 153 |
| NCT06237257Locally Advanced Cervical Cancer · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 2024 | 56 |
| NCT06222879Breast Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 31, 2026 | 350 |
| NCT06092268Advanced Solid Tumors | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Dec 2025 | 270 |
| NCT05794477Advanced Solid Tumor · China | 2 | Completed | Jiangsu HengRui Medicine | Aug 20, 2024 | 16 |
| NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2027 | 258 |
| NCT05482568Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 324 |
| NCT05444088Advanced Hepatocellular Carcinoma · China | 2 | Recruiting | Jiangsu HengRui Medicine | Jun 30, 2026 | 129 |
| NCT05416775Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Jiangsu HengRui Medicine | Jun 30, 2026 | 168 |
| NCT05353361Breast Neoplasms · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 31, 2025 | 402 |
| NCT05198817Advanced Malignant Tumors · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 31, 2023 | 240 |
| NCT05082545Advanced Malignant Tumors · Australia | 1 | Completed | Jiangsu HengRui Medicine | Jul 17, 2023 | 19 |
| NCT04979390Neoplasms | 1 | UNKNOWN | Jiangsu HengRui Medicine | Feb 10, 2022 | 15 |
| NCT04691063Small Cell Lung Carcinoma · China | 3 | By invitation | Jiangsu HengRui Medicine | May 15, 2025 | 486 |
| NCT04316364Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 15, 2023 | 537 |
| NCT04041011Small Cell Lung Carcinoma · China | 1 | Completed | Jiangsu HengRui Medicine | Apr 23, 2021 | 23 |
| NCT03995472Advanced Malignancies · Australia, China | 1 | Completed | Jiangsu HengRui Medicine | Jan 12, 2023 | 14 |
| NCT03732508Advanced Esophageal Squamous Cell Cancer · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Nov 2019 | 30 |
| NCT03711305Small Cell Lung Carcinoma · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Oct 2022 | 462 |
| NCT03474289Neoplasms · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 30, 2019 | 134 |
| NCT03133247Advanced Solid Tumors · Australia | 1 | Completed | Jiangsu HengRui Medicine | Apr 9, 2019 | 37 |
How it is read
Names in the registry
- “SHR-1316”, 8 entries
- “Adebrelimab”, 6 entries
- “Adebrelimab Injection”, 4 entries
- “adebrelimab + SHR-A2009”, 3 entries
- “HRS-717 + HRS-4642+SHR-1316;”, 3 entries
Codes read as this program: SHR1316.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Small Cell Lung Carcinoma, 6 studies
- Pancreatic Neoplasms, 3 studies
- Neoplasms, 3 studies
- Breast Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.